Munguva pfupi yapfuura, GenFleet yakazivisa data razvino rechikamu chechipiri chekudzidza kweKROCUS, fulzerasib (GFH925, KRAS G12C inhibitor) pamwe chete necetuximab yekurapa kenza yemapapu isiri diki (NSCLC) yekutanga, muchidimbu chakaitwa pamusangano wepagore weEuropean Lung Cancer Conference (ELCC) wegore ra2025.
Fulzerasib ndiyo mushonga wekutanga weKRAS G12C inhibitor wakagadzirwa neChina uyo wakagamuchirwa uye wakapihwa nePriority Review Designation neNMPA. Fulzerasib yakagamuchirawo Breakthrough Therapy Designations gore rino yekurapa varwere veKRAS G12C-mutant NSCLC vane kenza yemudumbu imwe chete uye varwere veCRC vakagamuchira kurapa kwemudumbu kaviri. Mhuri yemapuroteni eRAS inogona kukamurwa muzvikamu zveKRAS, HRAS neNRAS. Kuchinja kweKRAS kunowanikwa muvanhu vanosvika 90% vekenza yepancreatic, 30-40% yekenza yemudumbu, uye 15-20% yevarwere vekenza yemapapu. Kuonekwa kweKRAS G12C mutation subset kunowanzoonekwa kupfuura avo vane ALK, ROS1, RET uye TRK 1/2/3 mutations zvakabatana. GFH925 mushonga mutsva, unoshanda nemuromo, une simba weKRAS G12C inhibitor yakagadzirirwa kunanga kuchinjana kweGTP/GDP, danho rinokosha mukushanda kwenzira, nekushandura mapuroteni eKRAS G12C anoramba aripo pamwe chete uye asingadzoreki. Zvidzidzo zvekusarudza cysteine zvisati zvaitwa zvakaratidza kusarudza kwakanyanya kwefulzerasib kuenda kuG12C. Zvadaro, fulzerasib inodzivirira nzira yechiratidzo yekudzika kwemvura kuti iite kuti masero egomarara apfuure uye kuti masero amire.
Varwere veKRAS G12C-mutant NSCLC makumi mana nevanomwe vakanga vasati varapwa vakarapwa nefulzerasib pamwe chete necetuximab (fulzerasib 600mg BID + cetuximab 500 mg/m2 Q2W) kubva musi wa14 Ndira, 2025.
Kushanda: Pazuva rekupedzisira redata, pakati pevarwere makumi mana nevashanu vakaongororwa bundu mushure mekurapwa, ORR yaive 80% uye DCR yaive 100%; 57.8% vaive nebundu diki re ≥ 50%. Varwere gumi nevatanhatu (34%) vaive nebundu rakapararira muuropi; pakati pevarwere gumi nevana vakaongororwa bundu mushure mekurapwa, ORR pa RECIST 1.1 yaive 71.4%. Nguva yepakati yekupindura (DoR) yakanga isati yasvika, uye varwere makumi maviri nevana vaive vachiri kurapwa neavhareji yekutevera kwemwedzi gumi.1. MPFS yaive mwedzi gumi nemaviri nehafu uye mOS yakanga isati yasvika.
Kuchengetedzeka: Kubva pazuva rekupedzisira redata, mushonga wekubatanidza wakaita kuti pave nekuchengetedzeka/kushivirira kwakanaka. TRAEs dzakaitika mu87.2% yevarwere uye vazhinji veTRAEs vakaiswa mamakisi 1-2; 14.9% yevarwere vakasangana neTRAEs imwe chete yegiredhi rechitatu; hapana TRAEs yegiredhi 4-5. Varwere vaviri vakasangana nezviitiko zvakakomba zvine chekuita nekurapwa (TRSAE) uye TRSAEs dzakaongororwa kuti dzaingova ne cetuximab chete; varwere vatatu vakasangana neTRAEs, dzisina chekuita ne fulzerasib, zvikaita kuti pave nekumira kwedose. KROCUS yakaratidza kuderera kwekumira kwedose kana kudzikiswa pakati pezvidzidzo zvakasiyana zvekutanga zveG12C-mutant NSLCL. Hapana zviratidzo zvitsva zvekuchengetedza zvakaonekwa zvichienzaniswa ne fulzerasib kana cetuximab semushonga mumwe chete.
Parizvino, kuchine miedzo yakawanda yekiriniki yehunyanzvi hutsva hwekurwisa gomarara muChina huri kutsvaga varwere. Kana muchida kubvunzana nezvemishonga mitsva netekinoroji, munogona kubata Dhipatimendi reBeijing South Region Oncology Hospital International.
Nhamba yefoni: 4008803716
Email：myimmnet@163.com
Nguva yekutumira: Kubvumbi-15-2025